| 许柳柳,朱洁晨,卞 宏,于海容,朱述阳.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺疗效及对CRP、SaO2、PH水平影响[J].,2020,(22):4369-4372 |
| 布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺疗效及对CRP、SaO2、PH水平影响 |
| Effect of Budesonide Formoterol Combined with Tiotropium Bromide Inhalation on COPD and Its Effect on CRP, SaO2, and PH Levels |
| 投稿时间：2020-02-27 修订日期：2020-03-22 |
| DOI：10.13241/j.cnki.pmb.2020.22.038 |
| 中文关键词: 布地奈德福莫特罗 噻托溴铵吸入剂 慢性阻塞性肺病 |
| 英文关键词: Budesonide formoterol Tiotropium bromide inhaler Chronic obstructive pulmonary disease |
| 基金项目:江苏省推动科技创新项目（KC19041） |
|
| 摘要点击次数: 572 |
| 全文下载次数: 347 |
| 中文摘要: |
| 摘要 目的：探究布地奈德福莫特罗联合噻托溴铵吸入剂对慢阻肺治疗效果及对患者C-反应蛋白（C reaction protein，CRP）、血氧饱和度（arterial oxygen saturation，SaO2）以及肺动脉高压（pulmonary Hypertension，PH）的影响。方法：选择2016年至2019年于我院接受治疗的82例慢性阻塞性肺病患者，按照随机数字表法将其均分为两组（各41例），对照组单纯接受布地奈德福莫特罗治疗，研究组在对照组基础上加用噻托溴铵吸入剂施治，对比两组治疗有效率，治疗前后的第1秒用力呼气容积（forced expiratory volume in one second，FEV1）、用力肺活量（forced vital capacity，FVC）、第1秒用力呼气容积占预计值百分比（Percentage of FEV1 in the predicted value，FEV1%）、二氧化碳分压（carbon dioxide partial pressure，PaCO2）、SaO2、PH值、CRP。结果：（1）研究组治疗有效率明显高于对照组（P<0.05）；（2）治疗前两组FEV1、FVC、FEV1%对比无差异（P>0.05），治疗后研究组上述指标均高于对照组（P<0.05）；（3）治疗前两组SaO2、PaCO2、PH值对比无差异（P>0.05），治疗后研究组SaO2、PH值均高于对照组，PaCO2低于对照组（P<0.05）；（4）治疗前两组CRP水平无差异（P>0.05），治疗后研究组上述因子水平均低于对照组（P<0.05）。结论：布地奈德福莫特罗联合噻托溴铵吸入剂对慢阻肺具有较好的治疗效果，能够显著改善患者肺功能及血气指标，同时还能够缓解患者炎性状态。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of budesonide formoterol combined with tiotropium bromide in the treatment of COPD and its effects on CRP, SaO2, and PH in patients. Methods: 82 patients with chronic obstructive pulmonary disease who were treated in our hospital from 2016 to 2019 were selected, and they were divided into study group and control group (41 patients in each group) according to the random number table method. The control group received pure budesonide formoterol treatment, and the study group were treated with tiotropium bromide inhalation on the basis of the control group. Compare the treatment effectiveness of the two groups, FEV1, FVC, FEV1%, PaCO2, SaO2, PH value, CRP, before and after treatment. Results: (1) The treatment efficiency of the study group was significantly higher than that of the control group(P<0.05). (2) The differences in FEV1, FVC, and FEV1% between the two groups before treatment were not statistically significant (P>0.05), and the above indicators in the study group were higher than those in the control group after treatment(P<0.05). (3) The difference in SaO2, PaCO2, and PH values between the two groups before treatment was not statistically significant(P>0.05). After treatment, the SaO2 and PH values in the study group were higher than the control group, and PaCO2 was lower than the control group (P<0.05). (4) The differences in CRP levels between the two groups before treatment were not statistically significant (P>0.05). The levels of the above factors in the study group were lower than those in the control group after treatment (P<0.05). Conclusion: Budesonide formoterol combined with tiotropium bromide has a better therapeutic effect on COPD and can significantly improve the lung function of patients And blood gas indicators, while also alleviating the patient's inflammatory state. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
